High FGL2 expression is associated with tumour progression and poor survival in a number of different cancers, such as glioblastoma multiforme28,30,31, colorectal32, lung12, renal33, liver25,34,35, and prostate cancer36. This evidence concerns the gene FGL2 and neoplasm.